Cala Health, the non-invasive bioelectronic medicine leader, today announced it has completed the initial closing of an oversubscribed $50 million growth round, co-led by Vertex Growth Fund and Nexus ...
SEOUL, South Korea, Dec. 9, 2024 /PRNewswire/ -- Seoul National University Bundang Hospital ("SNUBH"), CurePSP, Inc. ("CurePSP") and GemVax & KAEL Co., Ltd. ("GemVax"; KOSDAQ: 082270) have announced ...
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III ...
Week trial J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San Francisco, CA NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- (“Anavex” or the “Company”) (Nasdaq: AVXL), a ...
A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for treating cognitive symptoms in Parkinson’s disease, a condition currently ...
BioArctic begins patient dosing in EXIST phase 2a study in Parkinson’s disease: Stockholm Saturday, December 7, 2024, 18:00 Hrs [IST] BioArctic AB (publ), a Swedish research-bas ...
The new Marie Skłodowska-Curie Doctoral Network AIPD is dedicated to investigating artificial intelligence methods to combat Parkinson's disease. It ...
STOCKHOLM, Sweden I 5, 2024 I BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab ...